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The microtubule-associated protein tau regulates
myriad neuronal functions, such as microtubule
dynamics, axonal transport and neurite outgrowth.
Tauopathies are neurodegenerative disorders char-
acterized by the abnormal metabolism of tau, which
accumulates as insoluble neuronal deposits. The
adult human brain contains equal amounts of
tau isoforms with three (3R) or four (4R) repeats
of microtubule-binding domains, derived from the
alternative splicing of exon 10 (E10) in the tau tran-
script. Several tauopathies are associated with im-
balances of tau isoforms, due to splicing deficits.
Here, we used a trans-splicing strategy to shift the
inclusion of E10 in a mouse model of tauopathy
that produces abnormal excess of 3R tau. Modu-
lating the 3R/4R ratio in the prefrontal cortex led
to a significant reduction of pathological tau accu-
mulation concomitant with improvement of neuronal
firing and reduction of cognitive impairments. Our
results suggest promising potential for the use of
RNA reprogramming in human neurodegenerative
diseases.
INTRODUCTION
Tau is a microtubule-associated protein, enriched in neuronal
axons, that regulates neurite outgrowth and axonal transport,
among other functions (Arendt et al., 2016; Medina et al., 2016;
Morris et al., 2011). Under pathological conditions, such as
gene mutations, failures in post-translational processing or
clearance (reviewed in Bodea et al., 2016), hyperphosphorylated
insoluble tau accumulates in the neuronal soma. These tau
deposits are the hallmark of several diseases, referred to as
tauopathies, which include Alzheimer’s disease and frontotem-This is an open access article under the CC BY-Nporal dementia with parkinsonism linked to chromosome 17
(FTDP-17) (reviewed in Spillantini and Goedert, 2013).
Human tau is encoded by the MAPT gene, comprising 16
exons that produce six different tau isoforms in the adult brain,
by alternative splicing of exons 2, 3, and 10 (Andreadis, 2005).
Alternative splicing of exon 10 (E10) gives rise to tau isoforms
with three (3R) or four (4R) microtubule-binding repeats (Andrea-
dis et al., 1992; Goedert et al., 1989), found in equal amounts in
the normal adult human brain. Imbalances in tau 3R/4R ratio are
known as a disease-causative phenomenon, initially based on
genetic evidence from patients carrying mutations affecting
E10 splicing (Hutton et al., 1998; Spillantini et al., 1998). So far,
more than 50 mutations have been found in the MAPT gene
(Qian and Liu, 2014; Spillantini and Goedert, 2013), with about
one-third of them affecting E10 splicing and consequently the
normal 3R/4R balance (Niblock and Gallo, 2012). The majority
of those mutations favor E10 inclusion, leading to 4R increase
(Spillantini and Goedert, 2013), but mutations yielding 3R excess
were also linked with disease (Stanford et al., 2003), suggesting
that tau isoform imbalance is detrimental regardless of whether
the ratio shifts toward 3R or 4R (reviewed in Andreadis, 2012).
Although their etiology is known, no treatment has become avail-
able for those tauopathies; yet, early correction of aberrant E10
splicing arises as a potential therapeutic strategy to stop the
onset of disease.
We previously validated the spliceosome-mediated RNA
trans-splicing (Rodriguez-Martin et al., 2005) as a procedure to
modulate endogenous tau E10 inclusion in the mouse brain
(Avale et al., 2013) and in human neurons in culture (Lacovich
et al., 2017). Here, we used this strategy to investigate whether
modulation of relative content in tau isoforms prevents the devel-
opment of pathological phenotypes in the htau mouse (Andorfer
et al., 2003), a validated model of tauopathy. Htau mice carry a
full-length human MAPT gene that produces the six human tau
isoforms in the adult brain, where production of 3R isoforms
are favored over 4R. It was suggested that such 3R > 4R content
might underlie tau pathology and the associated phenotypes
observed in aged htau mice, such as tau hyperphosphorylationCell Reports 23, 709–715, April 17, 2018 ª 2018 The Authors. 709
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(Andorfer et al., 2003) and cognitive deficits (Polydoro et al.,
2009). To test this hypothesis, we used trans-splicing to enhance
E10 inclusion into themedial prefrontal cortex of adult htaumice.
Trans-splicing reduced the contents of pathological tau in htau
mice, which showed normal electrophysiological and behavioral
performance, suggesting that early modulation of 3R/4R tau iso-
forms ratio has a beneficial effect over the tauopathy phenotypes
in this model.
RESULTS
Reprogramming of 3R to 4R Tau Isoforms in the
Prefrontal Cortex of Htau Mice
Tau pathology was reported both in the cortex and hippocampus
of htau mice (Andorfer et al., 2003; Polydoro et al., 2009). Yet we
found the most prominent accumulation of pathological tau in
the medial prefrontal cortex (mPFC) (Figure S1). Moreover, the
phenotypes we observed in this model are consistent with pre-
frontal dysfunction, so we selected the mPFC to modulate the
3R/4R ratio and analyze the potential functional rescue.
To promote E10 inclusion into endogenous tau transcripts,
we used a pre-trans-splicing molecule (PTM), delivered by a
lentiviral vector, (LV)-PTM4R (Figure 1A), as previously described
(Avale et al., 2013). The trans-splicing reaction yields a chimeric
RNA containing E10+, which codes for a 4R tau isoform. Control
mice were injected with an LV carrying the same construct but
lacking the trans-splicing domain (LV-PTM4R-DTSD; Figure 1B).
LV-PTMswere injected at 2–3months of age, before the onset of
pathological tau accumulation. Behavioral, electrophysiological,
and biochemical analyses were performed in 10- to 12-month-
old mice (Figure 1C).
Endpoint RT-PCR (Figure 1D) was performed to visualize tau
mRNA isoforms using primers spanning exons 9–13 of the tau
transcript. As previously reported (Avale et al., 2013), htau
mice produce very low amounts of E10+, which increased
after PTM4R administration (htau-PTM4R). To perform a
quantitative analysis of tau mRNA isoforms, real-time qPCR
was performed after laser-captured microdissection of the
mPFC co-injected with LV-PTMs and a fluorescent reporter
(LV-GFP; Figure 1E). Htau-control mice showed excess of
E10 over E10+ tau mRNA, yielding E10+/E10 ratio of 0.5
(Figures 1F and S1D). Conversely, htau-PTM4R showed an
increase in E10+ concomitant with a decrease in E10 (Fig-
ure S1D), leading to a ratio of 0.8 (Figure 1F). As expected,
the injection of trans-splicing molecules did not alter total
tau mRNA amounts (Figure 1G), both htau-PTM4R and htau-
control-injected mice showed similar total tau levels as non-in-
jected (NI) htau mice.
Western blot analyses using 3R and 4R specific antibodies
showed that htau-control mice display 2-fold 3R tau protein
over 4R tau, while htau-PTM4R mice showed similar 3R and
4R tau protein levels in the PFC (Figures 1H and S2A). As ex-
pected, wild-type (WT) mice evidenced almost all 4R content,
with very low amounts of 3R tau. Total tau levels were similar
between htau-control, htau-PTM4R, and htau non-injected
groups (Figure 1I), which in turn show increased total tau levels
compared with the WT group (Figures 1I and S2A), consistent
with previous reports (Andorfer et al., 2003; Duff et al., 2000).710 Cell Reports 23, 709–715, April 17, 2018The control vector (LV-PTM4R-DTSD) did not alter tau contents
in htau mice (Figure 1I) or in WT mice (Figure S2B). The injection
of LV-PTM4R drove E10 inclusion in the mPFC and adjacent M2
cortex, but not in other brain areas where the 3R > 4R imbalance
was observed in htau-PTM4R mice (Figure S2C). Together,
these data highlight the efficiency and specificity achieved with
the trans-splicing strategy to locally modulate 3R/4R ratio into
the adult htau brain.
Reduction of Insoluble and Hyperphosphorylated Tau in
Htau-PTM4R Mice
Accumulation of insoluble hyperphosphorylated tau is a hallmark
of human tau pathology, recapitulated in htau mice (Andorfer
et al., 2003; Castillo-Carranza et al., 2015; Duff et al., 2000;
Noble et al., 2009). To determine whether early modulation of
the 3R/4R ratio could prevent tau pathology, we analyzed the
accumulation of hyperphosphorylated tau in brain sections
spanning the mPFC of aged mice (>12 months) that had
been injected at 3 months with either LV-PTM4R (htau-PTM4R)
or LV-PTM4R-DTSD vector (htau-control). Htau-control mice
showed strong phospho-tau labeling along the PFC (Figures
2A–2D), detected by two different specific antibodies recog-
nizing tau phosphorylated at Ser 202 (CP13; Figure 2A) or at
Thr231/Ser235 (AT-180; Figure 2C). Quantitative analyses re-
vealed that in the htau-PTM4R group, the number of positive
cells stained with both antibodies was significantly reduced
compared with htau controls (Figures 2B and 2D).
Total amounts of hyperphosphorylated tau were also
measured by western blotting in PFC homogenates of aged
htau-PTM4R, htau-control, and WT mice (Figures 2E and 2F).
A significant increase was observed in htau-control mice
compared with WT mice, either at Ser 202 (Figures 2E and
S2D) or at Thr231/Ser235 (Figure 2F), while htau-PTM4R mice
showed values similar to WT mice (Figures 2E, 2F, and S2D).
We also quantified tau protein levels in soluble and insoluble
protein fractions obtained from PFC homogenates by sarkosyl
fractionation. Htau-control mice showed high amounts of insol-
uble tau (Figure 2G), yielding a 4-fold increase in the insoluble/
soluble ratio compared with WT (Figure 2H), while htau-PTM4R
mice showed a significant reduction in the insoluble tau fraction
(Figure 2G), leading to a soluble/insoluble tau ratio similar to con-
trol WT mice (Figure 2H). Taken together, these results indicate
that early local modulation of tau 3R/4R balance prevents the
accumulation of insoluble/hyperphosphorylated tau in the PFC
of aged htau mice.
Electrophysiological and Behavioral Phenotypes of
Htau-PTM4R Mice
To assess whether a functional recovery could be achieved
because of tau isoform modulation in the PFC of htau mice,
we characterized the neuronal firing in aged mice, recording
the electrophysiological activity of putative pyramidal neurons.
Three tetrodes were placed in the mPFC of anesthetized mice,
either htau-control, htau-PTM4R, or WT group, and extracellular
unit activity was analyzed according to published criteria (de Al-
meida et al., 2013). Normal neuronal activity was disrupted in the
htau-control group, which displayed a significant decrease in
mean firing rate compared with age-matched controls (Figures
Figure 1. Local Reprogramming of 3R to 4R Tau Isoforms in the Prefrontal Cortex of Htau Mice
(A and B) Map of lentiviral vectors. (A) LV-PTM4R used for trans-splicing and the expected chimeric transcript containing E10. (B) Lentiviral vector
LV-PTM4RDTSD used for control mice.
(C) Time course of the experiments performed in the study.
(D) Analysis of tau isoforms by endpoint RT-PCR with primers spanning E9 and E13.
(E) Laser-capture microdissection of the mPFC of htau mice co-injected with LV-PTM and an LV carrying GFP.
(F) Relative content of tau isoforms determined by RT-qPCR with specific primers for 3R (E10) and 4R (E10+). Data are expressed as the isoform ratio;
mean ± SEM; *p < 0.05, two-tailed t test; n = 4 per group.
(G) Total tau mRNA, showing no differences among treatments.
(H and I) Western blot detection of tau protein contents in PFC homogenates. (H) Tau isoforms 3R and 4R contents and (I) total tau protein, related to actin loading
control. Mean ± SEM; **p < 0.01 and ***p < 0.001, two-tailed t test (WT = 3, htau-control = 4, and htau-PTM4R = 5, htau Ni = 3). Full blots are shown in Figure S2A.
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Figure 2. Hyperphosphorylated and Insoluble Tau Contents in the PFC
(A–D) Hyperphosphorylated tau detected by immunohistochemistry using CP13 (S202) (A and B) and AT180 (T231/S235; C and D) antibodies in coronal sections
spanning themPFC. (B and D) Quantification of positive cells in htau-control and htau-PTM4R. CP13, n = 3 per group; AT180, n = 4 per group; two to four sections
per mouse; mean ± SEM; **p < 0.01 and ***p < 0.001, two-tailed t test.
(E and F) Hyperphosphorylated tau protein contents determined by western blot in PFC homogenates using CP13 (E) in WT (n = 4), htau-control (n = 6), and htau-
PTM4R (n = 6) or (F) AT180: WT (n = 3), htau-control (n = 4), and htau-PTM4R (n = 7). Mean ± SEM; *p < 0.05, one-way ANOVA followed by Tukey’s post hoc test.
Full blots are shown in Figure S2D.
(G and H) Sarkosyl insolubility assay. Soluble and insoluble fractions obtained from PFC homogenates were immunoblotted (G) to quantify total tau in each
fraction (H). WT, n = 2; htau-control, n = 4; htau-PTM4R, n = 3; mean ± SEM; *p < 0.05, one-way ANOVA followed by Tukey’s post hoc test.3A, 3B, S3C, and S3D). Remarkably, balancing 3R/4R tau
isoforms in htau-PTM4R mice resulted in a recovery of neuronal
activity, with a mean firing rate similar to the observed WT mice
(Figures 3B and S3C). Furthermore, the population of active neu-
rons firing over 4 Hz was decreased in htau-control mice
compared with WT (WT, 21.4%; htau, 7.7%; chi-square p =
0.034) and was recovered in hTau-PTM4R (WT, 21.4%; htau-
PTM4R, 25.5%; chi-square p = 0.59) (Figure 3B).
We next analyzed cognitive performance in the novel object
recognition (NOR) test, a task known to rely on mPFC integrity
(Morici et al., 2015), which is severely impaired in htaumice (Cas-
tillo-Carranza et al., 2014; Polydoro et al., 2009). As previously
reported, aged htau-control mice exhibited poor recognition per-
formance, showing a discrimination index of 50%, compared
with the 80%observed in theWT group (Figure 3C). Interestingly,712 Cell Reports 23, 709–715, April 17, 2018htau-PTM4R mice showed similar performance as WT to
discriminate the novel object (Figure 3C), demonstrating full re-
covery on this task. The time spent in exploration was similar be-
tween groups (Figure 3D). Yet an open-field analysis revealed a
small increase in total locomotion in htau-control mice compared
with WT (Figure 3E), with more activity in the center of the arena
(Figure 3F). However, these phenotypes were only partially
rescued in the htau-PTM4R group, showing no differences
from WT and htau-control groups. On the other hand, when
tested in the elevated plus maze, htau-control mice displayed
about 50% of entries into open arms (Figures 3G and 3H), sug-
gesting no preference for protected arms, while htau-PTM4R
mice showed 33% entries, similar to WT mice. However, no sta-
tistically significant differences were observed between groups
on this task. Moreover, in our hands the htau model did not
Figure 3. Functional Recovery in Htau-PTM4R Mice
(A and B) Electrophysiological activity in the PFC.
(A) Accumulated firing frequency of putative pyramidal neurons during 30 min
in WT (n = 4), htau-control (n = 3), and htau-PTM4R (n = 3) mice.
(B) Firing rate of all recorded units for each experimental group. Each dot
represents themean firing rate of a putative pyramidal unit recorded in the PFC
during 30 min. Red bars indicate mean firing rate of the entire population of
single units recorded per group; htau-ctrl was significative different (p < 0.05
versus WT, Kruskal-Wallis H2,183 = 6.8, p = 0.0329). WT, n = 84; htau control,
n = 52; and htau-PTM4R, n = 47 neurons from four, three, and three mice,
respectively.
(C and D) Novel object recognition task. (C) Discrimination ratio of the novel
object and (D) total time exploring objects (WT, n = 16; htau-control, n = 14;
htau-PTM4R, n = 13). Individual data are shown in Figures S3D and S3E.
(E and F) Spontaneous locomotion in the open field. (E) Total distance traveled
and (F) activity ratio in the center of the arena recorded during 30 min. WT, n =
11; htau-control, n = 8; and htau-PTM4R, n = 4. Data in (C)–(F) are mean ±
SEM; *p < 0.05 and **p < 0.01, one-way ANOVA followed by Tukey’s test.
Individual data points are shown in Figure S3C.
(G and H) Elevated plus maze task. (G) Percentage of entries into open arms
and (H) time spent in open arms. Mean ± SEM, n = 4. No significant differences
among groups (Kruskal-Wallis non-parametric test). Individual data are shown
in Figure S3F.show impairments in spatial memory assessed in the Morris wa-
ter maze test; both control and htau-PTM4R mice performed
similarly to WT mice (Figures S3A and S3B). Together, electro-
physiological and behavioral analyses indicate that the local
early modulation of tau isoforms in htau mice prevents impair-
ments in PFC functionality and restores normal performance in
the NOR task.
DISCUSSION
In this study we show that modulation of 3R/4R tau isoform bal-
ance in the prefrontal cortex precludes tau pathology and related
phenotypes in the htau mouse model of tauopathy.
The use of mouse models to analyze tau isoform imbalance is
challenging, because 4R is the only isoform present in the WT
adult mouse brain. By contrast, the htau model bears a full-
length normal human MAPT transgene that, despite the lack of
mutations, favors E10 exclusion and produces an excess of 3R
isoform. This might be due to the lack of specific splicing regula-
tory elements in themouse neurons (or a different combination of
splicing factors), which impairs the correct processing of the hu-
man tau transcript. Thus, compared with either the adult human
brain expressing both isoforms in an equimolar ratio or with WT
adult mouse brain, which expresses 4R tau only, the htau brain
has an aberrant content of tau isoforms that correlates with tau
pathology (Andorfer et al., 2003). Moreover, tau pathology is
not likely to be due to tau overexpression in this model, as the
same transgene in a WT background does not recapitulate tau-
opathy (Duff et al., 2000), suggesting that endogenousmurine 4R
tau might balance the excess of human 3R tau. These features
make the htaumodel particularly interesting to test in vivo strate-
gies that modulate E10 splicing and assess the phenotypic
consequences of such modulation.
We have demonstrated herein that by increasing E10 inclu-
sion, we reached a balanced 3R/4R ratio in the mPFC of
htau-PTM4R mice, which prevents the pathological phenotypes
observed under 3R excess in htau-control mice. It is note-
worthy that trans-splicing strategy reduces tau pathology
without changes in the total amount of tau protein compared
with control htau, and creating a 1.0 3R/4R ratio of human
tau in adult mice is not detrimental. Indeed, in our conditions,
the increase of the 4R isoform by means of the trans-splicing
strategy did not induce tau pathology; instead, consistent rescue
was observed in histological, functional, and behavioral ana-
lyses. Strikingly, enhancing 4R isoform by intraventricular ASO
treatment was reported to induce tau pathology and seizures
in young htau mice (Schoch et al., 2016). However, that study
was performed at 4 months of age, before the onset of the phe-
notypes we and others analyzed in the htau model (Andorfer
et al., 2003; Castillo-Carranza et al., 2015; Polydoro et al.,
2009). On the other hand, ASO intracerebroventricular (i.c.v.)
administration likely drives global 4R increase in the whole brain,
which clearly differs from our strategy that locally targets a
specific affected brain area. Our present results, in context
with previous reports using this model, suggest that the long-
term 3R > 4R imbalance might underlie tau pathology, particu-
larly prefrontal dysfunction, in aged htau mice, which can be
prevented by balancing the 3R/4R ratio at an early stage.Cell Reports 23, 709–715, April 17, 2018 713
We have shown here that trans-splicing reprogramming of the
endogenous tau transcript in vivo is a suitable strategy to achieve
a phenotypic recovery. Our previous work (Lacovich et al., 2017)
highlights the feasibility of this strategy to modulate tau isoform
balance in human neurons, independent of the predominant
isoform. Furthermore, RNA reprogramming can also correct
missense mutations inside E10 (Rodriguez-Martin et al., 2009),
without changing the total levels of tau protein. In this context,
tau RNA reprogramming by trans-splicing arises as a versatile
gene therapy approach with promising perspectives for human
tauopathies. Further studies would be needed to optimize treat-
ment conditions that ensure the most efficient therapeutics
effects.
EXPERIMENTAL PROCEDURES
Mice
All animal procedures were designed in accordance with the NIH Guidelines
for the Care and Use of Laboratory Animals, and protocols were approved
by the Institutional Committee of INGEBI-CONICET (protocol number 005/
2016) and FCEyN, University of Buenos Aires. Mice were housed under a
12 hr dark/light cycle with ad libitum access to food andwater. Htau transgenic
mice were obtained from Jackson Laboratories (stock number 005491) and
bred to obtain htau and WT colonies. All mice were genotyped as previously
described (Andorfer et al., 2003). Male adult mice were used to conduct all
the experiments described in this study.
LVs
Tau PTMs were delivered into LVs, prepared as detailed previously (Avale
et al., 2013) and in Supplemental Experimental Procedures.
Stereotaxic Injections
Malemice aged 8–10weeks (weight 25–30 g) were bilaterally injected with 2 mL
of lentiviral suspension (0.6 3 107 TU/mL) into the PFC at the following coor-
dinates (Paxinos and Franklin, 2011): anteroposterior, +2.5 mm; lateral, ±
0.5 mm; and dorsoventral, 2.5 and 1.5 mm, measured from the bregma.
Surgery was performed under the protocol detailed in Supplemental Experi-
mental Procedures.
Laser-Capture Microdissection
Fluorescent areas were cut out of a series of eight to ten sections using the
ArcturusXT laser-capture microdissection system (Thermo Fisher Scientific)
by infrared (IR) laser energy combined with a UV cutting laser (Supplemental
Experimental Procedures). Total RNA was isolated from the collected tissue
(0.5–1 mm3), yielded 0.5–1 mg RNA per sample.
Detection of Tau mRNA Isoforms
Total RNA was extracted using the RNeasy Lipid Tissue Kit (QIAGEN) or, in
laser-capture microdissection (LCM)-dissected tissue, with the PicoPure
RNA extraction Kit (Thermo Fisher Scientific). Reverse transcription was per-
formed using TaqMan RT (Applied Biosystems) with 0.5 mg of RNA and an
equimolar ratio of oligo(dT) and random hexamers. Endpoint PCR was per-
formed with primers spanning exons 9–13, as previously described (Avale
et al., 2013). Human 4R, 3R, and total tau mRNA isoforms were detected using
real-time PCR with specific pairs of primers per each isoform either spanning
E9–E10 or E9/11–E11, respectively, or for all human tau isoforms spanning at
E7–E8 (Supplemental Experimental Procedures).
Immunohistochemistry
Phosphorylated tau was detected on free-floating coronal sections (40 mm)
with either CP13 (1:100) or AT180 (1:500) (Thermo Fisher Scientific) mono-
clonal antibodies and developed with 3,30-diaminobenzidine (DAB) (Sigma-Al-
drich). Positive cells were quantified in the PFC between +1.54 and +2.5 mm
from bregma.714 Cell Reports 23, 709–715, April 17, 2018Protein Extraction and Western Blotting
PFC homogenates were separated on 12% SDS-polyacrylamide gels, trans-
ferred, and blotted using antibodies directed against 3R tau (1:2,000 anti-tau
3-repeat isoform RD3; mouse monoclonal; Millipore), 4R tau (1:1,000 anti-
tau 4-repeat isoform RD4; mouse monoclonal; Millipore), total tau (1:10,000
rabbit polyclonal; Dako), phospho-Ser202 (CP13 monoclonal, 1:300), AT-
180 (1:1,000; Thermo Fisher Sientific), or mouse b-actin (mouse monoclonal,
1:10,000; Abcam). See details in Supplemental Experimental Procedures.
Sarkosyl Insolubility Assay
Fractionation of soluble and insoluble proteins was performed as previously
described (Noble et al., 2009; Andorfer et al., 2003). Briefly, brains were ho-
mogenized, incubated with 1% sarkosyl reagent (Sigma-Aldrich), and ultra-
centrifuged to obtain soluble (supernatant) and insoluble (pellet) fractions
(Supplemental Experimental Procedures). Total tau was detected on each
fraction by western blot using total tau (1:10,000, rabbit polyclonal; Dako).
Electrophysiological Recordings
In vivo electrophysiological experiments we conducted as described previ-
ously (de Almeida et al., 2013). See Supplemental Experimental Procedures.
Behavioral Tests
All mice tested were sibling cohorts of males aged 10–12months. Experiments
were performed between 13:00 and 17:00 under dim illumination, in a sepa-
rated behavioral room, where mice were transferred in advance. Behavioral
experiments were analyzed by double-blinded operators.
Open Field
Activity boxes (Med Associates) were used to assess horizontal activity and
trajectories, as previously described (Avale et al., 2004). See details in Supple-
mental Experimental Procedures.
Elevated Plus Maze
This test was performed as described previously (Avale et al., 2004). See de-
tails in Supplemental Experimental Procedures.
Novel Object Recognition
The protocol was performed similarly to that previously described (Polydoro
et al., 2009), with minor modifications following a well-described methodolog-
ical procedure (Leger et al., 2013). Briefly, in the training phase mice were al-
lowed to explore identical objects for 10 min, and 5 hr later, mice were tested
for 5min in the same chamber with a familiar and a novel object. Discrimination
index was calculated as the time spent exploring the novel object divided by
the total time spent exploring both objects (familiar and novel). See details in
Supplemental Experimental Procedures.
Statistical Analyses
Data were analyzed using GraphPad Prism. When normal distribution was
assumed, the three experimental groups were analyzed using one-way
ANOVA, followed by Tukey’s test. When indicated, paired comparisons were
done using two-tailed Student’s t test. When normal distribution could not
be assumed, the Kruskal-Wallis non-parametric test was used to compare
groups.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.03.079.
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